145 related articles for article (PubMed ID: 32683269)
1. The FLUKA Monte Carlo code coupled with an OER model for biologically weighted dose calculations in proton therapy of hypoxic tumors.
Dahle TJ; Rusten E; Stokkevåg CH; Silvoniemi A; Mairani A; Fjæra LF; Rørvik E; Henjum H; Wright P; Boer CG; Forsback S; Minn H; Malinen E; Ytre-Hauge KS
Phys Med; 2020 Aug; 76():166-172. PubMed ID: 32683269
[TBL] [Abstract][Full Text] [Related]
2. Combined RBE and OER optimization in proton therapy with FLUKA based on EF5-PET.
Henjum H; Dahle TJ; Mairani A; Pilskog S; Stokkevåg C; Boer CG; Redalen KR; Minn H; Malinen E; Ytre-Hauge KS
J Appl Clin Med Phys; 2023 Sep; 24(9):e14014. PubMed ID: 37161820
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia adapted relative biological effectiveness models for proton therapy: a simulation study.
Garrido-Hernandez G; Henjum H; Høiskar MK; Dahle TJ; Redalen KR; Ytre-Hauge KS
Biomed Phys Eng Express; 2022 Nov; 8(6):. PubMed ID: 36260973
[TBL] [Abstract][Full Text] [Related]
4. A systematic approach for calibrating a Monte Carlo code to a treatment planning system for obtaining dose, LET, variable proton RBE and out-of-field dose.
Tjelta J; Fjæra LF; Ytre-Hauge KS; Boer CG; Stokkevåg CH
Phys Med Biol; 2023 Nov; 68(22):. PubMed ID: 37820690
[No Abstract] [Full Text] [Related]
5. Hypoxia-informed RBE-weighted beam orientation optimization for intensity modulated proton therapy.
Ramesh P; Ruan D; Liu SJ; Seo Y; Braunstein S; Sheng K
Med Phys; 2024 Mar; 51(3):2320-2333. PubMed ID: 38345134
[TBL] [Abstract][Full Text] [Related]
6. Inclusion of a variable RBE into proton and photon plan comparison for various fractionation schedules in prostate radiation therapy.
Ödén J; Eriksson K; Toma-Dasu I
Med Phys; 2017 Mar; 44(3):810-822. PubMed ID: 28107554
[TBL] [Abstract][Full Text] [Related]
7. Exploration and application of phenomenological RBE models for proton therapy.
Rørvik E; Fjæra LF; Dahle TJ; Dale JE; Engeseth GM; Stokkevåg CH; Thörnqvist S; Ytre-Hauge KS
Phys Med Biol; 2018 Sep; 63(18):185013. PubMed ID: 30102240
[TBL] [Abstract][Full Text] [Related]
8. RBE and OER within the spread-out Bragg peak for proton beam therapy: in vitro study at the Proton Medical Research Center at the University of Tsukuba.
Kanemoto A; Hirayama R; Moritake T; Furusawa Y; Sun L; Sakae T; Kuno A; Terunuma T; Yasuoka K; Mori Y; Tsuboi K; Sakurai H
J Radiat Res; 2014 Sep; 55(5):1028-32. PubMed ID: 24876271
[TBL] [Abstract][Full Text] [Related]
9. Monte Carlo simulations of therapeutic proton beams for relative biological effectiveness of double-strand break.
Wang CC; Hsiao Y; Lee CC; Chao TC; Wang CC; Tung CJ
Int J Radiat Biol; 2012 Jan; 88(1-2):158-63. PubMed ID: 21823821
[TBL] [Abstract][Full Text] [Related]
10. A phenomenological relative biological effectiveness approach for proton therapy based on an improved description of the mixed radiation field.
Mairani A; Dokic I; Magro G; Tessonnier T; Bauer J; Böhlen TT; Ciocca M; Ferrari A; Sala PR; Jäkel O; Debus J; Haberer T; Abdollahi A; Parodi K
Phys Med Biol; 2017 Feb; 62(4):1378-1395. PubMed ID: 28114106
[TBL] [Abstract][Full Text] [Related]
11. Introducing Proton Track-End Objectives in Intensity Modulated Proton Therapy Optimization to Reduce Linear Energy Transfer and Relative Biological Effectiveness in Critical Structures.
Traneus E; Ödén J
Int J Radiat Oncol Biol Phys; 2019 Mar; 103(3):747-757. PubMed ID: 30395906
[TBL] [Abstract][Full Text] [Related]
12. Proton Treatment Techniques for Posterior Fossa Tumors: Consequences for Linear Energy Transfer and Dose-Volume Parameters for the Brainstem and Organs at Risk.
Giantsoudi D; Adams J; MacDonald SM; Paganetti H
Int J Radiat Oncol Biol Phys; 2017 Feb; 97(2):401-410. PubMed ID: 27986346
[TBL] [Abstract][Full Text] [Related]
13. Nuclear interactions in proton therapy: dose and relative biological effect distributions originating from primary and secondary particles.
Paganetti H
Phys Med Biol; 2002 Mar; 47(5):747-64. PubMed ID: 11931469
[TBL] [Abstract][Full Text] [Related]
14. The influence of hypoxia on LET and RBE relationships with implications for ultra-high dose rates and FLASH modelling.
Jones B
Phys Med Biol; 2022 Jun; 67(12):. PubMed ID: 35545062
[No Abstract] [Full Text] [Related]
15. Validation of the physical and RBE-weighted dose estimator based on PHITS coupled with a microdosimetric kinetic model for proton therapy.
Takada K; Sato T; Kumada H; Koketsu J; Takei H; Sakurai H; Sakae T
J Radiat Res; 2018 Jan; 59(1):91-99. PubMed ID: 29087492
[TBL] [Abstract][Full Text] [Related]
16. Relative biological effectiveness variation along monoenergetic and modulated Bragg peaks of a 62-MeV therapeutic proton beam: a preclinical assessment.
Chaudhary P; Marshall TI; Perozziello FM; Manti L; Currell FJ; Hanton F; McMahon SJ; Kavanagh JN; Cirrone GA; Romano F; Prise KM; Schettino G
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):27-35. PubMed ID: 24986743
[TBL] [Abstract][Full Text] [Related]
17. Implementation of a double scattering nozzle for Monte Carlo recalculation of proton plans with variable relative biological effectiveness.
Fjæra LF; Indelicato DJ; Stokkevåg CH; Muren LP; Hsi WC; Ytre-Hauge KS
Phys Med Biol; 2020 Nov; 65(22):. PubMed ID: 33053524
[TBL] [Abstract][Full Text] [Related]
18. Biological dose and complication probabilities for the rectum and bladder based on linear energy transfer distributions in spot scanning proton therapy of prostate cancer.
Pedersen J; Petersen JBB; Stokkevåg CH; Ytre-Hauge KS; Flampouri S; Li Z; Mendenhall N; Muren LP
Acta Oncol; 2017 Nov; 56(11):1413-1419. PubMed ID: 29037095
[TBL] [Abstract][Full Text] [Related]
19. Spot Scanning and Passive Scattering Proton Therapy: Relative Biological Effectiveness and Oxygen Enhancement Ratio in Cultured Cells.
Iwata H; Ogino H; Hashimoto S; Yamada M; Shibata H; Yasui K; Toshito T; Omachi C; Tatekawa K; Manabe Y; Mizoe JE; Shibamoto Y
Int J Radiat Oncol Biol Phys; 2016 May; 95(1):95-102. PubMed ID: 27084632
[TBL] [Abstract][Full Text] [Related]
20. Influence of beam pruning techniques on LET and RBE in proton arc therapy.
Henjum H; Tjelta J; Fjæra LF; Pilskog S; Stokkevåg CH; Lyngholm E; Handeland AH; Ytre-Hauge KS
Front Oncol; 2023; 13():1155310. PubMed ID: 37731633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
